Disc Medicine to Present New Data on Two Rare Blood Disease Therapies at SOHO 2026

Key Takeaways

• Disc Medicine (NASDAQ: IRON) will present clinical data across its hematology portfolio at the SOHO 2026 Annual Meeting, September 9–12 in Houston, Texas.
• Highlights include an oral presentation of initial Phase 2 data from the RESTORE-PV trial testing DISC-3405 in polycythemia vera, and new Phase 2 RALLY-MF data on DISC-0974 for myelofibrosis-related anemia.
• A third poster will examine the patient-reported burden of anemia in myelofibrosis, drawn from a systematic literature review.

Disc Medicine, a clinical-stage biopharmaceutical company focused on hematologic diseases, announced it will share data from multiple programs in its pipeline at this year's Society of Hematologic Oncology (SOHO) Annual Meeting.

The centerpiece is an oral presentation of initial data from the Phase 2 RESTORE-PV study evaluating DISC-3405, an anti-TMPRSS6 monoclonal antibody, in patients with polycythemia vera. The presentation will include baseline and safety data from 40 patients across two cohorts, along with pharmacokinetic, pharmacodynamic, and efficacy data from 20 patients in Cohort A. CEO John Quisel said the company is looking forward to sharing this first clinical readout, noting that together with its myelofibrosis data, the presentations reflect progress across its portfolio of therapies for myeloproliferative neoplasms.

Alongside the polycythemia vera data, Disc Medicine will present new results from its RALLY-MF study of DISC-0974, an anti-hemojuvelin antibody being developed to treat anemia associated with myelofibrosis. Both the RESTORE-PV and RALLY-MF data will be presented orally on Thursday, September 10, and will also appear as posters the day before.

A separate poster, based on a systematic literature review, will characterize the "humanistic burden" of anemia in myelofibrosis patients using patient-reported outcomes data.

Both DISC-0974 and DISC-3405 remain investigational and are not yet approved for use in any market. Disc Medicine, headquartered in Watertown, Massachusetts, is developing a pipeline of potentially first-in-class therapies targeting heme biosynthesis and iron homeostasis pathways to treat serious blood disorders.